Journal
JCO ONCOLOGY PRACTICE
Volume 16, Issue 11, Pages 745-+Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/OP.20.00295
Keywords
-
Categories
Funding
- French Society for Oncology Pharmacy
Ask authors/readers for more resources
PURPOSE Patients with cancer are at higher risk for contracting the COVID-19 infection and are more likely to have higher morbidity and mortality. This is a big challenge for oncology teams that have to treat patients to avoid contamination by SARS-CoV-2. The aim of the current work is to present oncology pharmacy practice guidelines during the COVID-19 pandemic to secure the pharmaceutical care of patients with cancer. METHODS The bureau of the French Society for Oncology Pharmacy proposed these recommendations according to the French High Authority of Health following the Guidelines of Good Practice, slightly modified according to the pandemic crisis situation. These guidelines were developed by a working group of 7 experts in oncology pharmacy practice. Furthermore, the guidelines were assessed by 31 independent reviewers. RESULTS One hundred percent of reviewers approved the guidelines and 90% of them suggested some improvements. The final version incorporates the best comments and consists of 26 recommendations organized in 8 different sections. CONCLUSION These guidelines allow secure pharmaceutical management of patients with cancer during the COVID-19 pandemic. (c) 2020 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available